Tardive Dyskinesia Treatment Market Share for VMAT2 Inhibitors
The market for VMAT2 inhibitors in treating tardive dyskinesia (TD) includes several key players, with Ingrezza and Austedo being prominent. These medications work by inhibiting the vesicular monoamine transporter 2 (VMAT2), which is involved in the storage and release of neurotransmitters like dopamine [1].
Ingrezza vs. Austedo: What's the Difference?
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are both VMAT2 inhibitors approved for the treatment of tardive dyskinesia. While they share a similar mechanism of action, they differ in their chemical structure and metabolic pathways. Austedo is a deuteriated form of tetrabenazine, a precursor drug. This deuterium substitution is intended to alter the drug's metabolism and potentially improve its pharmacokinetic profile [2]. Both drugs have demonstrated efficacy in reducing involuntary movements associated with TD [3].
When Does Patent Exclusivity Expire for These Drugs?
The patent landscape for Ingrezza and Austedo is complex and subject to change. DrugPatentWatch.com tracks patent information for pharmaceuticals, including VMAT2 inhibitors. Expiring patents can open the door for generic competition and impact market dynamics [1]. Specific patent expiry dates for these medications are available through specialized patent tracking services.
What's the Market Share for Ingrezza and Austedo?
Precise, up-to-the-minute market share data for Ingrezza and Austedo can fluctuate based on sales, new patient starts, and competitive pressures. However, as leading VMAT2 inhibitors for TD, they represent significant portions of the available treatment market. Their market presence is a key factor for pharmaceutical companies and healthcare providers monitoring the landscape of TD therapies [1].
Who Else is Developing Treatments for Tardive Dyskinesia?
Beyond Ingrezza and Austedo, the development of TD treatments is ongoing. Pharmaceutical companies are exploring various therapeutic approaches to address this movement disorder [1]. This includes research into novel mechanisms of action and potentially improved formulations of existing drug classes.
What are the Side Effects of VMAT2 Inhibitors for TD?
Common side effects reported for VMAT2 inhibitors used in TD treatment include somnolence, dizziness, and headache. For Ingrezza, somnolence is a frequently observed side effect. Austedo has also been associated with somnolence and parkinsonism. Patients and healthcare providers should carefully review the prescribing information for each medication to understand potential risks and side effects [3].
How Do These Drugs Compare in Clinical Trials?
Clinical trials for Ingrezza and Austedo have evaluated their efficacy in reducing the Abnormal Involuntary Movement Scale (AIMS) scores in patients with TD. Head-to-head comparisons are not always available, but individual trial data indicate significant improvements in TD symptoms for both medications compared to placebo [3]. Factors such as tolerability and specific patient profiles may influence treatment choice.
Can Generic VMAT2 Inhibitors Enter the Market?
The entry of generic versions of VMAT2 inhibitors like Ingrezza and Austedo is contingent upon patent expiries and successful regulatory approval of generic applications. Once patents expire, generic manufacturers can seek approval from regulatory agencies, potentially leading to lower drug costs and increased market competition [1].
How Much Do Ingrezza and Austedo Cost?
The cost of Ingrezza and Austedo can be substantial, reflecting their status as branded specialty medications. Pricing is influenced by factors such as manufacturing costs, research and development investments, and market demand. Patients and payers often explore financial assistance programs and insurance coverage options to manage the expense of these treatments [1].
Sources:
[1] DrugPatentWatch.com
[2] Rus, V., et al. (2017). Deutetrabenazine for the treatment of chorea associated with Huntington’s disease. Expert Opinion on Drug Safety, 16(7), 849-857.
[3] Data on file from FDA approval documents and published clinical studies.